NaHS, an H2S donor, is a potential treatment for transverse aortic constriction (TAC)-induced myocardial fibrosis and Ang II-induced cardiac fibroblast proliferation by enhancing SIRT3 levels. The gene discussed is AGT; the disease is persistent truncus arteriosus.